Company intelligence / Profile preview
Alixer Nexgen Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Alixer Nexgen Therapeutics is a wholly owned innovation-focused subsidiary of Alkem Laboratories, established in 2024. The company is dedicated to research, innovation, and the development of novel medicines and biosimilars across various therapeutic areas, aiming to establish global collaborations for advanced treatments.
- Modalities
- BiosimilarsBiologicSmall molecule
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Alixer Nexgen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alixer Nexgen Therapeutics.